Answers are grounded in this paper and cite their sources.
Analysis describes demographics and treatment patterns in patients with NMOSD receiving inebilizumab.
This study aimed to describe demographics, disease characteristics, and treatment patterns among patients receiving inebilizumab in a real-world setting.
No takes yet. Share an insight, caveat, or question.
Levy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: